Side Effects Halle Berry Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Halle Berry Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Status: Confirmed HRT user. Berry has publicly disclosed her use of hormone therapy for menopause management in multiple interviews.
  • Drug class: Menopausal hormone therapy (MHT), commonly called HRT, which includes estrogen-based and combined estrogen-progestogen formulations.
  • Public platform: Founded Respin, a wellness brand with a strong focus on menopause education and advocacy.
  • Key public statements: Berry has discussed hot flashes, cognitive difficulties ("brain fog"), mood swings, insomnia, and the initial misdiagnosis of her perimenopause symptoms.
  • Clinical match: Every symptom Berry has described in public is cataloged in the FDA label for conjugated estrogens and in the Women's Health Initiative (WHI) trial literature as either a target symptom of treatment or a recognized adverse event.

Halle Berry's public menopause disclosure

Berry's advocacy for menopause awareness became a central part of her public identity starting around 2020. In interviews with outlets including AARP and CNN, she described being misdiagnosed during perimenopause, a period she said her doctors initially attributed to herpes rather than hormonal shifts. She was 45 at the time.

Berry has stated publicly that she uses hormone therapy. She founded Respin as a direct response to what she called the lack of conversation around menopause. In a 2022 appearance on the Tamron Hall Show, she described her journey from confusion about her symptoms to eventually finding a physician who prescribed HRT. She has also testified before the U.S. Congress in support of menopause research funding, further cementing her role as one of the most visible public advocates for women's midlife health care.

Hot flashes and vasomotor symptoms

Berry has described hot flashes as one of the most immediate symptoms she experienced during perimenopause. She has spoken about episodes of sudden, intense heat that disrupted her daily routine, particularly during filming.

From a clinical standpoint, vasomotor symptoms (VMS), which include hot flashes and night sweats, are the most common indication for prescribing MHT. The FDA-approved prescribing information for estradiol and conjugated estrogens lists "treatment of moderate to severe vasomotor symptoms due to menopause" as the primary indication. In the WHI trial, women receiving conjugated equine estrogens plus medroxyprogesterone acetate reported a significant reduction in hot flash frequency compared to placebo (JAMA, 2002).

VMS affect an estimated 75% of perimenopausal and postmenopausal women. Severity varies widely. Some women report mild warmth a few times per week; others experience 10 or more episodes daily, accompanied by sweating and flushing.

The HealthRX Medical Team take: Berry's description of hot flashes interfering with work is clinically consistent with moderate-to-severe VMS, the exact population for whom the Endocrine Society and the North American Menopause Society recommend considering systemic estrogen therapy. Her case illustrates why VMS severity, not just presence, drives treatment decisions.

Brain fog and cognitive changes

In multiple interviews, Berry has used the phrase "brain fog" to describe periods of difficulty concentrating, word-finding trouble, and a general feeling of mental sluggishness during perimenopause. She has described this symptom as one of the most alarming aspects of her experience because it initially made her fear a neurological condition.

Cognitive complaints during the menopause transition are well documented. The Study of Women's Health Across the Nation (SWAN) found measurable declines in processing speed and verbal memory during perimenopause, with partial recovery in postmenopause. The mechanism is thought to involve declining estradiol levels affecting hippocampal synaptic plasticity and prefrontal cortex function.

Whether HRT reverses these cognitive changes is a more complicated question. The WHI Memory Study (WHIMS) found that initiating combined HRT in women aged 65 and older was associated with increased dementia risk, but this population was years past the menopause transition. Observational data and the KEEPS-Cog trial suggest that estrogen started in early menopause may preserve, though not necessarily improve, cognitive function.

The HealthRX Medical Team take: Berry's brain fog is consistent with the perimenopause-associated cognitive profile described in SWAN. The timing matters clinically. Data on the "critical window" hypothesis suggests that estrogen therapy may support cognition when initiated near menopause onset, but the same therapy started a decade later may carry risk. Berry's public account suggests she began HRT relatively close to symptom onset, which aligns with current guideline recommendations from the North American Menopause Society.

Mood changes and emotional volatility

Berry has spoken publicly about mood swings, irritability, and episodes of feeling unlike herself during perimenopause. In her Congressional testimony and in interviews with Extra TV, she described emotional instability that she did not initially connect to hormonal changes.

The clinical literature supports a strong link between the menopause transition and mood disturbance. A meta-analysis published in JAMA Psychiatry found that perimenopausal women had a 1.5 to 3-fold increased risk of depressive symptoms compared to premenopausal women. Fluctuating estradiol levels are thought to affect serotonin and norepinephrine signaling.

Estrogen therapy has shown efficacy for perimenopausal depression in randomized trials. A landmark RCT by Soares et al. demonstrated that transdermal estradiol was superior to placebo for depressive episodes in perimenopausal women. The FDA does not approve estrogen as an antidepressant, but clinicians sometimes consider it as adjunctive therapy.

The HealthRX Medical Team take: Berry's description of mood changes that preceded her HRT use matches the perimenopausal depression phenotype. Her public account of these symptoms being dismissed or misattributed reflects a broader clinical problem: menopause-related mood disorders are frequently underdiagnosed because they overlap with major depressive disorder and generalized anxiety.

Insomnia and sleep disruption

Berry has mentioned sleep difficulties as part of her perimenopause experience, though she has discussed this symptom less extensively than hot flashes or brain fog in her public interviews.

Sleep disruption during menopause is common and multifactorial. Night sweats cause direct sleep fragmentation. Independent of VMS, declining estrogen and progesterone levels affect sleep architecture. The SWAN Sleep Study found that self-reported sleep difficulty increased during the menopause transition, with hot flashes and depressive symptoms as independent predictors.

Progesterone, often part of a combined HRT regimen for women with an intact uterus, has mild sedative properties mediated by its metabolite allopregnanolone, a GABA-A receptor modulator. Some women report improved sleep on combined HRT for this reason, though the FDA label for medroxyprogesterone does not list sleep improvement as an indication.

The HealthRX Medical Team take: Insomnia during the menopause transition can stem from nocturnal VMS, primary sleep architecture changes, or concurrent mood disturbance. Treating the underlying hormonal shift with MHT can improve sleep when VMS is the primary driver, but women whose insomnia persists on HRT may need targeted sleep interventions.

The misdiagnosis issue

One of the most clinically relevant parts of Berry's public story is her account of being misdiagnosed. She has stated that a physician initially attributed her symptoms to herpes rather than perimenopause. She was in her early 40s, an age when perimenopause commonly begins but is frequently overlooked.

This is not an isolated experience. A 2024 survey by the Menopause Society found that many women visit multiple physicians before receiving a menopause-related diagnosis. Medical education historically devoted minimal curriculum time to menopause. A survey published in Menopause found that the median time spent on menopause in U.S. medical school curricula was zero hours in some programs.

The HealthRX Medical Team take: Berry's experience with misdiagnosis reflects a systemic gap in menopause training. Her public advocacy, including Congressional testimony, has helped bring attention to this gap. From a patient safety perspective, the HealthRX Medical Team recommends that women in their 40s experiencing new-onset vasomotor, cognitive, or mood symptoms should ask specifically about perimenopause and request hormone level testing if symptoms are ambiguous.

Documented HRT side effects Berry has not publicly discussed

For completeness, the FDA label for systemic estrogen therapy lists several adverse events that Berry has not addressed publicly. These include breast tenderness, headache, nausea, bloating, and unscheduled vaginal bleeding. These side effects are dose-dependent and often improve with formulation adjustments.

More serious risks documented in the WHI and subsequent analyses include a small absolute increase in venous thromboembolism (primarily with oral estrogen), breast cancer risk with long-term combined estrogen-progestogen use (an additional 8 cases per 10,000 women-years in the WHI), and stroke. These risks are dose-, route-, and duration-dependent. Transdermal estradiol appears to carry lower thrombotic risk than oral formulations.

Berry has not publicly disclosed her specific HRT formulation, dosing, or route of administration, and the HealthRX Medical Team does not speculate about private medical details.

Frequently asked questions

›
›
›
›
›

References

  • Rossouw JE, Anderson GL, Prentice RL, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women." JAMA. 2002;288(3):321-333
  • Greendale GA, Huang MH, Wight RG, et al. "Effects of the menopause transition and hormone use on cognitive performance in midlife women." Neurology. 2009;72(21):1850-1857
  • Gleason CE, Dowling NM, Wharton W, et al. "Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the KEEPS Cognitive and Affective study." PLoS Med. 2015;12(6)
  • Soares CN, Almeida OP, Joffe H, Cohen LS. "Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women." Arch Gen Psychiatry. 2001;58(6):529-534
  • Kravitz HM, Zhao X, Bromberger JT, et al. "Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women." Sleep. 2008;31(7):979-990
  • Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. "Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women." BMJ. 2008;336(7655):1227-1231
  • FDA Prescribing Information: Conjugated Estrogens / Medroxyprogesterone Acetate. AccessData
  • The North American Menopause Society (NAMS). Hormone Therapy: Benefits and Risks